Tilray Brands Past Earnings Performance
Past criteria checks 0/6
Tilray Brands's earnings have been declining at an average annual rate of -54.4%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 21.1% per year.
Key information
-54.4%
Earnings growth rate
-34.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 21.1% |
| Return on equity | -9.8% |
| Net Margin | -47.4% |
| Last Earnings Update | 29 Feb 2024 |
Recent past performance updates
Recent updates
Tilray Could Break Down
Apr 07Tilray Brands, Inc.'s (NASDAQ:TLRY) Shares Climb 31% But Its Business Is Yet to Catch Up
Mar 27
Tilray: Big Opportunities Ahead In Germany And Alcohol Segment
Mar 12Tilray Brands (NASDAQ:TLRY) Is Carrying A Fair Bit Of Debt
Jan 25Tilray Remains Stuck In Neutral
Jan 10Tilray Brands, Inc.'s (NASDAQ:TLRY) Price Is Right But Growth Is Lacking
Dec 19Industry Analysts Just Upgraded Their Tilray Brands, Inc. (NASDAQ:TLRY) Revenue Forecasts By 13%
Oct 10Analysts Are Upgrading Tilray Brands, Inc. (NASDAQ:TLRY) After Its Latest Results
Oct 06Tilray Brands, Inc. (NASDAQ:TLRY) Shares Could Be 22% Below Their Intrinsic Value Estimate
Sep 18Little Excitement Around Tilray Brands, Inc.'s (NASDAQ:TLRY) Revenues
Apr 17An Intrinsic Calculation For Tilray Brands, Inc. (NASDAQ:TLRY) Suggests It's 28% Undervalued
Feb 03Tilray Brands, Inc.'s (NASDAQ:TLRY) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 09Tilray and other cannabis stocks soar as Biden calls for marijuana scheduling review
Oct 06Japan should permit medical cannabis, health ministry panel says
Sep 29Most Canadian cannabis LPs not following Aurora's decline after earnings disappointment
Sep 21Tilray's Canadian cannabis brand RIFF launches Drumsticks
Sep 15Tilray: Hype Train Crashed
Sep 08Revenue & Expenses BreakdownBeta
How Tilray Brands makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 29 Feb 24 | 743 | -352 | 242 | 0 |
| 30 Nov 23 | 700 | -1,430 | 233 | 0 |
| 31 Aug 23 | 651 | -1,443 | 229 | 1 |
| 31 May 23 | 627 | -1,453 | 231 | 1 |
| 28 Feb 23 | 596 | -1,792 | 228 | 1 |
| 30 Nov 22 | 603 | -578 | 234 | 1 |
| 31 Aug 22 | 614 | -501 | 228 | 1 |
| 31 May 22 | 628 | -477 | 233 | 2 |
| 28 Feb 22 | 617 | 42 | 217 | 2 |
| 30 Nov 21 | 589 | -275 | 193 | 2 |
| 31 Aug 21 | 564 | -375 | 181 | 1 |
| 31 May 21 | 513 | -367 | 156 | 1 |
| 28 Feb 21 | 468 | -521 | 143 | 1 |
| 30 Nov 20 | 462 | -243 | 144 | 1 |
| 31 Aug 20 | 426 | -149 | 138 | 2 |
| 31 May 20 | 405 | -103 | 128 | 2 |
| 29 Feb 20 | 387 | 22 | 117 | 2 |
| 30 Nov 19 | 338 | -63 | 119 | 1 |
| 31 Aug 19 | 263 | -16 | 105 | 1 |
| 31 May 19 | 179 | -25 | 97 | 1 |
| 28 Feb 19 | 92 | -28 | 80 | 1 |
| 30 Nov 18 | 43 | 63 | 55 | 1 |
| 31 Aug 18 | 34 | 27 | 44 | 1 |
| 31 May 18 | 28 | 23 | 34 | 0 |
| 28 Feb 18 | 24 | 25 | 22 | 0 |
| 30 Nov 17 | 20 | 18 | 16 | 0 |
| 31 Aug 17 | 18 | 15 | 14 | 0 |
| 31 May 17 | 15 | 3 | 10 | 0 |
| 28 Feb 17 | 13 | 6 | 9 | 0 |
| 30 Nov 16 | 11 | 2 | 7 | 0 |
| 31 Aug 16 | 9 | 1 | 6 | 0 |
| 31 May 16 | 6 | 0 | 5 | 0 |
| 29 Feb 16 | 5 | -1 | 4 | 0 |
| 30 Nov 15 | 3 | -3 | 3 | 0 |
| 31 Aug 15 | 1 | -4 | 3 | 0 |
| 31 May 15 | 0 | -5 | 3 | 0 |
| 28 Feb 15 | 0 | -5 | 3 | 0 |
| 30 Nov 14 | 0 | -3 | 3 | 0 |
| 31 Aug 14 | 0 | -3 | 2 | 0 |
| 31 May 14 | 0 | -1 | 1 | 0 |
Quality Earnings: TLRY is currently unprofitable.
Growing Profit Margin: TLRY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TLRY is unprofitable, and losses have increased over the past 5 years at a rate of 54.4% per year.
Accelerating Growth: Unable to compare TLRY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TLRY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: TLRY has a negative Return on Equity (-9.78%), as it is currently unprofitable.